card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Post COVID-19 reboot of clinical trials in Asia Pacific

White paper by Ken Lee, Cristina Chang, Vicky Yin, Patrice Hugo, Alan Metz, Jeffrey Spaeder
Home / Insights / Post COVID-19 reboot of clinical trials in Asia Pacific

Dr. Patrice Hugo recently co-authored a white paper with IQVIA about restarting clinical trials in Asia Pacific following the COVID-19 pandemic. The recent restrictions imposed by many countries in response to the COVID-19 outbreak has impacted ongoing clinical research, and restarting clinical trials is a critically important activity. This paper investigates how research sites are utilizing a variety of measures, including diagnostic tests, in an attempt to minimize risk of external transmission of the infection to staff and patients at the site.

Complete the form below to access this white paper